Dapsone may be combined with antibiotics such as rifampicin and clofazimine in multi-drug therapy for leprosy. However, concurrent use with other sulfonamides can increase the risk of hypersensitivity reactions, so clinicians usually avoid overlapping sulfa drugs unless specifically indicated.
Typical signs include dark (cola-colored) urine, sudden fatigue, jaundice, and a rapid drop in hemoglobin levels. Prompt laboratory testing and discontinuation of the drug are essential to prevent serious complications.
Mild hepatic impairment does not usually contraindicate Dapsone, but liver function should be monitored periodically because the drug is metabolized in the liver and rare hepatotoxicity has been reported.
Oral Dapsone works systemically to reduce neutrophil activity, while topical acne products act locally on the skin surface. Topical dapsone gels (5 %) are formulated for acne but are not the same as the oral capsule, which carries a higher risk of systemic side effects.
Dapsone is classified as category B3 in the UK, indicating limited data in humans. It should be avoided during pregnancy unless the potential benefit justifies the potential risk to the fetus, and only under specialist supervision.
Dapsone is not an antimalarial agent. Travelers should use proven prophylactic medications and avoid relying on Dapsone for malaria prevention.
Alcohol can exacerbate hemolysis and methemoglobinemia in susceptible individuals, so limiting alcohol intake while on Dapsone is advisable.
Dapsone is not listed on the World Anti-Doping Agency (WADA) prohibited list, but athletes should disclose its use to team physicians and verify that no prohibited metabolites are present in competition testing.
A mild, self-limiting rash can result from an initial hypersensitivity reaction as the immune system adjusts to the drug. If the rash progresses or is accompanied by fever, medical evaluation is required.
Clinical improvement in dermatitis herpetiformis or leprosy skin lesions typically begins within 2-4 weeks, though full therapeutic effect may require several months of continuous therapy.
Diaminodiphenyl sulfone, commonly known as Dapsone, is an antibacterial and anti-inflammatory agent classified within the skin-care therapeutic category. It is supplied as oral capsules packaged in a bottle, with a common pack size of up to 1000 capsules. In the United Kingdom Dapsone is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The medication is used principally for skin-related inflammatory conditions and certain infections.
Dapsone interferes with bacterial folate synthesis by inhibiting the enzyme dihydropteroate synthase, which is essential for the production of dihydrofolic acid. This antimicrobial action is most relevant in the treatment of Mycobacterium leprae (the bacterium that causes leprosy).
In dermatologic conditions, Dapsone’s anti-inflammatory effect is attributed to the suppression of neutrophil chemotaxis and the reduction of reactive oxygen species generated by activated neutrophils. The result is decreased skin inflammation and lesion formation. Oral absorption is rapid, with peak plasma concentrations reached within 2-6 hours. The drug has a relatively long elimination half-life of 20-30 hours, allowing once-daily dosing in most regimens. Metabolism occurs primarily in the liver via N-acetylation; the metabolites are excreted in urine.
These indications are recognised by the MHRA and align with the drug’s approved product licence in the United Kingdom.
Disclaimer: Off-label use of Dapsone must be overseen by a qualified healthcare professional, with individualized risk assessment and appropriate monitoring.
Absolute contraindications
Relative contraindications
Special populations
Patients should inform their prescriber of all prescription medicines, over-the-counter products, herbal supplements, and dietary habits before starting Dapsone.
Exact dosing must be individualized by the prescribing clinician based on indication, laboratory results, and patient tolerance.
Patients should report any new rash, dark urine, shortness of breath, or unexplained fatigue promptly.
This article provides educational information about Dapsone and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
